Loading clinical trials...

Echinocandins Versus Azoles for Candidemia Treatment | Clinical Trials | Clareo Health

COMPLETED

Echinocandins Versus Azoles for Candidemia Treatment

Echinocandins Versus Azoles as First-line Therapy for the Treatment of Candidemia in Intensive Care Units

NCT03799172•Hospices Civils de Lyon

Summary

Candidemia is the most frequent invasive fungal disease in intensive care units (ICUs). It remains a major health concern, considering its attributable mortality up to 40% in critically ill patients. Successful clinical outcome requires early diagnosis and effective antifungal therapy. Guidelines for the treatment of candidemia were published by the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). According to these guidelines, echinocandins are the preferred first-line therapy for candidemia in critically ill patients. Considering the bibliography supporting this statement, the place of triazoles still needs to be defined in candidemia therapeutic arsenal. In this context, we are setting up a retrospective cohort study using Hospital database to compare the efficacy of echinocandins and azoles for the treatment of candidemia in intensive care units.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients who had a diagnosis of candidemia during ICU stay and were treated with echinocandins or azoles

Exclusion Criteria

•Patients with neutropenia
•Patients without antifungal treatment
•Patients who received antifungal therapy for more than two days before candidemia diagnosis
•Patients receiving liposomal amphotericin b or multiple antifungal agents as first-line therapy
•Patients who received less than 4 days of antifungal therapy after candidemia diagnosis

Locations (1)

Hospices Civils de Lyon, Hôpital de la Croix-Rousse

Lyon, France

Key Dates

Start Date

November 1, 2018

Primary Completion Date

February 1, 2019

Completion Date

September 1, 2019

Last Updated

March 4, 2020

Enrollment

ACTUAL participants

Conditions

Candidemia

Interventions

Echinocandin treatment

DRUG

Triazole treatment

DRUG

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858

CandidemiaCandidiasis, Invasive

View study

TERMINATEDPHASE3

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

NCT05178862

Candidiasis, InvasiveCandidemia

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 4, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Echinocandins Versus Azoles for Candidemia Treatment

Inclusion Criteria

Exclusion Criteria

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

Prevalence and Epidemiology of Nosocomial Candidaemia and Antifungal Susceptibility Patterns in an Italian Tertiary-Care Hospital